{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:23Z","timestamp":1785526823666,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The clinical use of CD3\u2013CD20\u2013directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed\/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as \u0394PET parameters. Prognostic impact of DS and semi-quantitative PET metrics were determined for PFS\/OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline an whole-body MTV\u2009&gt;\u2009504.7\u00a0cm\u00b3 was associated with shorter median PFS of 1 vs. 3 months (HR\u2009=\u20095.6,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.00025; C-index\u2009=\u20090.94). At first follow-up, those with DS4\u20135 exhibited significantly higher risk of progression (HR\u2009=\u200911.42,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0182; C-index\u2009=\u20090.97) and shorter survival (HR\u2009=\u20097.07,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.059; C-index\u2009=\u20090.72). Non-achievement of \u2265\u200975.5% SUVmean reduction significantly increased risk for PFS (HR\u2009=\u20097.65;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0065; C-index\u2009=\u20090.92) and OS events (HR\u2009=\u200911.1;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001; C-index\u2009=\u20090.95).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, longitudinal semi-quantitative PET assessment identified patients at high risk of relapse and may enhance risk stratification and personalized management in BsAb-treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07958-4","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:18:15Z","timestamp":1780298295000},"page":"5982-5993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic role of FDG-PET in patients with relapsed\/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5006-7444","authenticated-orcid":false,"given":"Sophie","family":"Wollnitza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-2606","authenticated-orcid":false,"given":"David","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Freisleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristo","family":"Boyadzhiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Amon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Katharina","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Behringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"7958_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/648572","author":"N Sun","year":"2015","unstructured":"Sun N, Zhao J, Qiao W, et al. Predictive value of interim PET\/CT in DLBCL treated with R-CHOP: meta-analysis. BioMed Res Int. 2015;2015:648572. https:\/\/doi.org\/10.1155\/2015\/648572.","journal-title":"BioMed Res Int"},{"key":"7958_CR2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Key Points.Blood. 2017;130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03.","journal-title":"Epub ahead print"},{"key":"7958_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.122.264740","volume":"64","author":"L Michaud","year":"2023","unstructured":"MichaudL, Bantilan K, Mauguen A, et al. Prognostic Value of 18F-FDG PET\/CT in diffuse large b-cell lymphoma treated with a risk-adapted immunochemotherapy regimen. J Nucl Med. 2023;64:536\u201341. https:\/\/doi.org\/10.2967\/jnumed.122.264740.","journal-title":"J Nucl Med"},{"key":"7958_CR4","doi-asserted-by":"publisher","unstructured":"KimJ, Cho J, Lee MH et al. Lymphoid neoplasia car T cells vs bispecific antibody as third-or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144(6):629-638. https:\/\/doi.org\/10.1182\/blood.2023023419.","DOI":"10.1182\/blood.2023023419"},{"key":"7958_CR5","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus Gemcitabine and Oxaliplatin (GemOx) versus Rituximab-GemOx for relapsed or refractory diffuse large B-Cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404:1940\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(24)01774-4.","journal-title":"Lancet"},{"key":"7958_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"DickinsonMJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"7958_CR7","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2022","unstructured":"ThieblemontC, Phillips T, Ghesquieres, Herve, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol. 2022;41:2238\u201347. https:\/\/doi.org\/10.1200\/JCO.22.01725.","journal-title":"J Clin Oncol"},{"key":"7958_CR8","unstructured":"Jurczak W, Ghesquieres H, Karimi Y et al. The royal marsden Nhs foundation trust.\u00a02023.\u00a0https:\/\/journals.lww.com\/hemasphere\/pages\/default.aspx."},{"key":"7958_CR9","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","volume":"9","author":"E Shumilov","year":"2025","unstructured":"ShumilovE, Wurm-Kuczera R, Kerkhoff A, et al. Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study. Blood Adv. 2025;9:3865\u201377. https:\/\/doi.org\/10.1182\/bloodadvances.2024014903.","journal-title":"Blood Adv"},{"key":"7958_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2024-199330","volume":"144","author":"TR Brooks","year":"2024","unstructured":"Brooks TR, Zabor EC, Bedelu YB, et al. Real-world outcomes with bispecific T-Cell engagers (REALBiTE) for relapsed or refractory large B-Cell lymphoma: a multi-center, retrospective cohort study. Blood. 2024;144:111\u2013111.","journal-title":"Blood"},{"key":"7958_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"BrinkmannU, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182\u2013212. https:\/\/doi.org\/10.1080\/19420862.2016.1268307.","journal-title":"mAbs"},{"key":"7958_CR12","doi-asserted-by":"publisher","unstructured":"Shumilov E, Scholz J, Seib M et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. https:\/\/doi.org\/10.1182\/bloodadvances.2024015719\/2369400\/bloodadvances.2024015719.pdf","DOI":"10.1182\/bloodadvances.2024015719\/2369400\/bloodadvances.2024015719.pdf"},{"key":"7958_CR13","doi-asserted-by":"publisher","unstructured":"Magno G, Rejeski K, Seib M et al. Prognostic value of inflammation-based scores in R\/R LBCL patients treated with CD3xCD20 bispecific T-Cell engagers. https:\/\/doi.org\/10.1182\/bloodadvances.2025017766\/2417828\/bloodadvances.2025017766.pdf","DOI":"10.1182\/bloodadvances.2025017766\/2417828\/bloodadvances.2025017766.pdf"},{"key":"7958_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"ChesonBD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32:3059\u201367. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"7958_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01074-w","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wu X, Huang S, et al. Evaluation of therapeutic effect and prognostic value of 18F-FDG PET\/CT in different treatment nodes of DLBCL patients. EJNMMI Res. 2024;14(1):20. https:\/\/doi.org\/10.1186\/s13550-024-01074-w.","journal-title":"EJNMMI Res"},{"key":"7958_CR16","unstructured":"Zhu D, Xu X-L, Fang C et al. Prognostic value of interim 18 F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(9):15340\u201315350."},{"key":"7958_CR17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27103","author":"K Kitajima","year":"2019","unstructured":"Kitajima K, Okada M, Yoshihara K, et al. Predictive value of interim FDG-PET\/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. Oncotarget. 2019;10(52):5403\u20135411. https:\/\/doi.org\/10.18632\/oncotarget.27103.","journal-title":"Oncotarget"},{"key":"7958_CR18","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593\u2013605. https:\/\/doi.org\/10.1016\/S2352-3026(24)00166-2.","journal-title":"Lancet Haematol"},{"key":"7958_CR19","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.108.057307","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1. https:\/\/doi.org\/10.2967\/JNUMED.108.057307.","journal-title":"J Nucl Med"},{"key":"7958_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.9265","volume":"32","author":"SF Barrington","year":"2014","unstructured":"BarringtonSF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048. https:\/\/doi.org\/10.1200\/JCO.2016.68.9265.","journal-title":"J Clin Oncol"},{"key":"7958_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2014","unstructured":"BoellaardR, Delgado-Bolton R, Oyen WJG, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7958_CR22","first-page":"272","volume":"3","author":"SA Esfahani","year":"2013","unstructured":"Esfahani SA, Heidari P, Halpern EF, et al. Baseline total lesion glycolysis measured with 18F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3:272\u2013281.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7958_CR23","unstructured":"Hutchings M. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. https:\/\/findanexpert.unimelb.edu.au\/scholarlywork\/1837348-glofitamab-monotherapy-in-relapsed-or-refractory-large-b-cell-lymphoma--extended-follow-up-from-a-pivotal-phase-ii-study-and-subgroup-analyses-in-patients-with-prior-chimeric-antigen-receptor-t-cell-therapy-and-by-baseline-total-metabolic-tumor-volume"},{"key":"7958_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous Epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021;398:1157\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(21)00889-8.","journal-title":"Lancet"},{"key":"7958_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06554-0","volume":"51","author":"CA Voltin","year":"2023","unstructured":"VoltinCA, Paccagnella A, Winkelmann M, et al. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. Eur J Nucl Med Mol Imaging. 2023;51:1361\u20131370. https:\/\/doi.org\/10.1007\/s00259-023-06554-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7958_CR26","doi-asserted-by":"publisher","first-page":"E817","DOI":"10.1097\/HS9.0000000000000817","volume":"7","author":"CA Voltin","year":"2023","unstructured":"VoltinCA, G\u00f6del P, Beckmann L, et al. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy. Hemasphere. 2023;7:E817. https:\/\/doi.org\/10.1097\/HS9.0000000000000817.","journal-title":"Hemasphere"},{"key":"7958_CR27","doi-asserted-by":"publisher","unstructured":"ShumilovE, Ventura D, Carobin V et al. Title: Multiple time-point FDG-PET imaging for risk stratification of patients with relapsed\/refractory large B-cell lymphoma undergoing CD19-directed CAR-T cell therapy. Blood. 2025;146(Supplement 1):5491. https:\/\/doi.org\/10.1182\/blood-2025-5491.","DOI":"10.1182\/blood-2025-5491"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07958-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:51Z","timestamp":1785521091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7958"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07958-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this analysis was obtained from the Ethics Committee of Westphalia-Lippe and the Medical Faculty of the University of M\u00fcnster (approval no. [2025-314-f-S]).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in the figures.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sophie Wollnitza has received travel support from abbvie.\u00a0David Ventura has received a research grant from the clinician scientist program of the University of M\u00fcnster, outside of the submitted work.\u00a0Robert Seifert has received a travel grant from Boehringer Ingelheim Funds and a research grant from Else Kr\u00f6ner-Fresenius-Stiftung, as well as travel support and speaker honoraria from Novartis and Boston Scientific, outside of the submitted work.\u00a0Akhil Behringer has received travel support from Sanofi.\u00a0Julia Katharina Scholz has received travel grants from Abbvie, Novartis, Sobi.\u00a0Marcel Teichert is an advisor or consultant for Janssen-Cilag, has received honoraria from BMS\/Celgene, Janssen-Cilag, BPM Pharma, Medothic GmbH.\u00a0Andrea Kerkhoff has received honoraria and travel support from Abbvie, Alexion, Amgen, AstraZeneca, BeiGene, BMS, Lilly, Novartis, Roche, Recordati, Sobi, Takeda.\u00a0Fabian M\u00fcller has received research support from AstraZeneca, BMS, Kite\/Gilead, and Miltenyi Bioscience, has consulted for AstraZeneca, ArgoBio, BMS, CRISPR Therapeutic, EcoR1, Incyte, Janssen, Kite\/Gilead, Miltenyi Bioscience, Novartis, and Sobi and has received speaker\u2019s honoraria from Abbvie, AstraZeneca, Beigene, BMS, Incyte, Janssen, Kite\/Gilead, Miltenyi Bioscience, MSD, Novartis, Pfizer, Sobi, and Takeda.\u00a0Bastian von Tresckow is an advisor or consultant for AbbVie, Allogene, Amgen, BMS\/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Serb, Sobi and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS\/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche, Serb and Takeda; reports research funding from Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; is member of steering committees for Regeneron (Inst) and Takeda.\u00a0Georg Lenz received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. G.L. received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal\/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. The other authors declare no further competing financial interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}